12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Humira adalimumab: Phase III started

Abbott began the 56-week, open-label, international Phase III CALM trial to evaluate Humira plus prednisone and Imuran azathioprine in about 240 patients monitored with either stringent criteria or...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >